

MIRA INFORM REPORT

Report No. :	542078
Report Date :	29.11.2018

IDENTIFICATION DETAILS

Name :	BAYER HEALTHCARE LLC
Registered Office :	251 Little Falls Drive, Wilmington, New Castle State: DE Postal Code: 19808
Country :	United States
Financials (as on) :	2017 [Summarized]
Date of Incorporation :	1953
Legal Form :	Limited Liability Company
Line of Business :	Subject develops, manufactures, and markets healthcare and medical products
No. of Employees :	800

RATING & COMMENTS

(Mira Inform has adopted New Rating mechanism w.e.f. 23rd January 2017)

MIRA's Rating :	A+
------------------------	----

Credit Rating	Explanation	Rating Comments
A+	Low Risk	Business dealings permissible with low risk of default

Maximum Credit Limit :	USD 1 000 000
Status :	Good
Payment Behaviour :	Regular
Litigation :	Clear

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

ECGC Country Risk Classification List

Country Name	Previous Rating (30.06.2018)	Current Rating (30.09.2018)
United States	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

UNITED STATES - ECONOMIC OVERVIEW

The US has the most technologically powerful economy in the world, with a per capita GDP of \$59,500. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.

In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.

Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.

The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.

Imported oil accounts for more than 50% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at \$840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.

The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a \$700 billion Troubled Asset Relief Program in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and former President Barack OBAMA signed a bill providing an additional \$787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.

Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through FY 2018, the direct costs of the wars will have totaled more than \$1.9 trillion, according to US Government figures.

In March 2010, former President OBAMA signed into law the Patient Protection and Affordable Care Act (ACA), a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016,

through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.

In July 2010, the former president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.

The Federal Reserve Board (Fed) announced plans in December 2012 to purchase \$85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed ended its purchases during the summer of 2014, after the unemployment rate dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of GDP. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With continued low growth, the Fed opted to raise rates several times since then, and in December 2017, the target rate stood at 1.5%.

In December 2017, Congress passed and President Donald TRUMP signed the Tax Cuts and Jobs Act, which, among its various provisions, reduces the corporate tax rate from 35% to 21%; lowers the individual tax rate for those with the highest incomes from 39.6% to 37%, and by lesser percentages for those at lower income levels; changes many deductions and credits used to calculate taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do not obtain the minimum amount of health insurance required under the ACA. The new taxes took effect on 1 January 2018; the tax cut for corporations are permanent, but those for individuals are scheduled to expire after 2025. The Joint Committee on Taxation (JCT) under the Congressional Budget Office estimates that the new law will reduce tax revenues and increase the federal deficit by about \$1.45 trillion over the 2018-2027 period. This amount would decline if economic growth were to exceed the JCT's estimate.

Source : CIA

STATUTORY INFORMATION

Order	Bayer HealthCare LLC
Address in the order	12809 Shawnee Mission United States (the address in the order corresponds to one of the company's branches)
Legal Name	BAYER HEALTHCARE LLC
Trade Name	BAYER / BAYER HEALTHCARE
ID	ID
ID Details	3536270
Creation Date	1953
Incorporation Date	10/16/2002
Legal Address	REGISTERED AGENT INFORMATION Name: CORPORATION SERVICE COMPANY Address: 251 LITTLE FALLS DRIVE City: WILMINGTON County: New Castle State: DE Postal Code: 19808 Phone: 302-636-5401
Operative Address	100 Bayer Boulevard Whippany, NJ 07981 USA
Telephone	862-404-3000
Fax	862-404-3000
Legal Form	Limited Liability Company
E-Mail	bhc.fb@bayer.com / contactbayer@bayer.com
Registered In	DELAWARE
Website	www.bayer.us
Contact	Rebecca Jolley, Senior Vice President, Commercial Head
Staff	800 employees
Activity	SIC Code 2834, Pharmaceutical Preparations NAICS Code 325412, Pharmaceutical Preparation Manufacturing

BANKS

Name of Bank

Reported Amount

There are not informed banks

Description

The company does not make its banking data public.

HISTORY

History

The company was founded in 1953

Key Developments

Bayer HealthCare LLC Presents at Bio-IT World
Conference & Expo, May-15-2018

Apr 26 18

Bayer HealthCare LLC Presents at Bio-IT World
Conference & Expo, May-15-2018 . Venue: Seaport
World Trade Center, Boston, Massachusetts, United
States.

Bayer HealthCare LLC Presents at KNeCT365 Life
Sciences' BioProcess International West 2018, Mar-19-
2018 through Mar-22-2018

Mar 13 18

Bayer HealthCare LLC Presents at KNeCT365 Life
Sciences' BioProcess International West 2018, Mar-19-
2018 through Mar-22-2018. Venue: Hilton San
Francisco Union Square, San Francisco, California,
United States. Presentation Date & Speakers: Mar-21-
2018, Ashley Hesslein, Associate Director in Biological
Development, Kirk McLean, Senior Development
Scientist, Shawn Liu, Chief Scientist & Department
Head, Tad Thomas, Director and Global Lead,
Biologics Process Transfer and Launch Global
Biological Development. Mar-22-2018, Ashley
Hesslein, Associate Director in Biological Development,
Shawn Liu, Chief Scientist & Department Head, Yuval
Shimoni, Principal Engineer.

Bayer HealthCare LLC Presents at Redefining Early
Stage Investments Conference, Jan-09-2018

Jan 8 18

Bayer HealthCare LLC Presents at Redefining Early
Stage Investments Conference, Jan-09-2018 . Venue:
Marines' Memorial Club & Hotel, 609 Sutter St., San



MIRA INFORM PRIVATE LIMITED
605, Palmspring, Near D'Mart, Link Road,
Malad (West), Mumbai - 400 064. INDIA
Tel : 91-22-40448000 (44 lines)
Fax : 91-22-40448045 / 40448046
E-mail : mira@mirainform.com
info@mirainform.com
Website : <http://www.mirainform.com>
<http://www.miraglobalcheck.com>
<http://www.miraglobalcollections.com>

Parent Company

Francisco, California, United States.

The company is a subsidiary of Bayer Aktiengesellschaft, founded in 1863.

PRINCIPAL ACTIVITY

General Description

Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products.

Service/Product Description

DIVISIONS:
Pharmaceuticals
Consumer Health
Crop Science
Animal Health

The company offers blood glucose monitoring systems, diabetes self-care software, and lancing devices; and YAZ, a low-dose oral contraceptive. It also provides diagnostic testing for urinalysis, DCA, immunology, blood gas, and hematology; molecular and clinical chemistry testing to assess and manage health in a myriad of disease states, including cardiovascular, kidney and infectious diseases, oncology, and virology; and Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms, including nausea, phonophobia, and photophobia. The company offers an array of products and technologies addressing the diagnostic needs of healthcare sciences, such as automation and integration, clinical chemistry, hematology, immunodiagnosics, information systems, HIV assays, hepatitis assays, systems and software, blood gases, diabetes and glycated hemoglobin, and urinalysis. It provides diagnostic systems, point of care testing, molecular diagnostics, laboratory automation, and productivity solutions and services to hospitals and healthcare systems, laboratories, and physicians' offices. It also provides animal health, consumer care, and pharmaceutical solutions.

Sales

Wholesale and Retail

Operations Area

National and International

Imports From

Hong Kong, China and Taiwan

Export To

Worldwide

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Employees 800 employees
Payments With Suppliers Regular

BRANDS

Brand	Comments
Acceleron	NA
Adalat	NA
Adempas	NA
Adengo	NA
Advantage	NA
Advantix	NA
Advocate	NA
Afrin	NA
Agroeste	NA
Aleve	NA
Alion	NA
Aliqopa	NA

CLIENTS

Name of Client	Country	Comments
BAYER DE MEXICO SA DE CV	MEXICO	NA
COVANCE MEXICO SERVICES, S. DE R.L. DE C.V.	MEXICO	NA
LABORATORIOS ZEYCO SA DE CV	MEXICO	NA
DISTRIBUIDORA MEDICA DIAGNOSTICA SAC	PERU	NA
BAYER SA	ECUADOR	NA
BAYER S.A.	COLOMBIA	NA

Comments The company's main clients include national companies, international businesses and private customers.

SUPPLIERS

Supplier Name	Country	Comments
VINCENT MEDICAL MFG. CO., LTD.	HONG KONG	NA
GUANGZHOU LEAD FAIR PLASTIC CO., LTD.	CHINA	NA
PVI CHEMICAL CO., LTD	TAIWAN	NA
Comments	-	

LOCATION

Headquarters	100 Bayer Boulevard Whippany, NJ 07981 USA
Branches	The company has many branches in USA, such as:
	8850 59th Ave N.E., 97305 Brooks, OR
	1200 Anderson Corner / 2804 Hwy 95 / 1050 Anderson Corner, 83660 Parma, ID
	800 Dwight Way, 94710 Berkeley
	455 Mission Bay Blvd. South, 94158-2144 San Francisco, CA
	890 Embarcadero Drive, 95605 West Sacramento



MIRA INFORM PRIVATE LIMITED
605, Palmspring, Near D'Mart, Link Road,
Malad (West), Mumbai - 400 064. INDIA
Tel : 91-22-40448000 (44 lines)
Fax : 91-22-40448045 / 40448046
E-mail : mira@mirainform.com
info@mirainform.com
Website : <http://www.mirainform.com>
<http://www.miraglobalcheck.com>
<http://www.miraglobalcollections.com>

BAYER HEALTHCARE LLC - 542078

PAGE NO. : 10

3310 Pasadena Blvd., 77503 Pasadena, TX

408 East 50th Street Lubbock, 79404 Lubbock

12707 Shawnee Mission Parkway, 66216-1846
Shawnee Mission, KS

8400 Hawthorn Road, 64120 Kansas City , MO

800 N Lindbergh Blvd, 63141 Creve Coeur, MO

3030 Jackson Ave, 38112 Memphis

4207 Michigan Avenue, Road NE, 37323 Cleveland,
TN

Keystone Technology Park - Bldg III, 407 Davis Drive,
27560 Morrisville

801 Pennsylvania Avenue, NW, Suite 745, 20004
Washington D.C.

400 West Stoever Avenue, 17067-1418 Myerstown, PA

625, Alpha Drive (Heilman Center), 15238-2819

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Pittsburgh

36 Columbia Road, 07962-1910 Morristown, NJ

3930 Edison Lakes Parkway, 46545-3465 Mishawaka,
IN

1740 Whitehall Road, 49445 Muskegon, MI

Industries

12707 Shawnee Mission Pkwy, Shawnee, KS 66216
NA

GROUP STRUCTURE AND SUBDIARY COMPANIES

Listed at the stock exchange

NO

Capital

NA

Shareholders (%)

This is a private company. The company does not disclose information on shareholders. The following information has been obtained through private sources and could not be confirmed:

The company is a subsidiary of Bayer Aktiengesellschaft

Information about Bayer Aktiengesellschaft

Activity:

The company is a German multinational pharmaceutical and life sciences company.

Address:

Kaiser-Wilhelm-Allee 1
Leverkusen 51373
Germany

Management

Telephone:
49 214 30 1

Website:
www.bayer.com Sector: Healthcare

Industry:
Drug Manufacturers - Major

Full Time Employees:
118,196

Key Executive:
Werner Baumann, Chairman and Chief Executive Officer
Rebecca Jolley, Senior Vice President, Commercial Head
Steve Neumann, Vice President Consumer Insights
Feridun Ozdil, Executive Vice President of Research and Development
Erica L. Mann, President of Consumer Care Division
Joyce J. Lee, President of North American Animal Health Business
Joerg Heidrich, Senior Vice President, Global Head, Product Supply -Biotech and Site Head
Philip Blake, Bayer HealthCare Representative U.S.A. NA

Subsidiary Companies

Related Companies

Bayer USA Foundation
In 1953, Bayer created the first of three foundations that later all merged to become the Bayer USA Foundation. It has a programmatic focus on education and workforce development, environment and sustainability.

Other subsidiaries of Bayer Aktiengesellschaft:

Adverio Pharma GmbH Schönefeld, Germany
AgrEvo Verwaltungsgesellschaft mbH Frankfurt am Main, Germany
Alcafleu Management GmbH & Co. KG Schönefeld, Germany
AO Bayer Moscow, Russia
Bayer (Proprietary) Limited Isando, South Africa
Bayer (Schweiz) AG Zurich, Switzerland
Bayer 04 Immobilien GmbH Leverkusen, Germany
Bayer 04 Leverkusen Fußball GmbH Leverkusen, Germany

Bayer A / S Copenhagen, Denmark
Bayer AB Solna, Sweden
Bayer Agriculture Limited Cambridge, U.K.
Bayer Algerie S. P. A. Algiers, Algeria
Bayer Altersversorgung GmbH Leverkusen, Germany
Bayer Animal Health GmbH Leverkusen, Germany
Bayer AS Oslo, Norway
Bayer Austria Gesellschaft m. b. H. Vienna, Austria
Bayer B. V. Mijdrecht, Netherlands
Bayer Beteiligungsverwaltung Goslar GmbH
Leverkusen, Germany
Bayer Bitterfeld GmbH Bitterfeld-Wolfen, Germany
Bayer Bulgaria EOOD Sofia, Bulgaria
Bayer Business Services GmbH Leverkusen, Germany
Bayer Capital Corporation B. V. Mijdrecht, Netherlands
Bayer Chemicals Aktiengesellschaft Leverkusen,
Germany
Bayer Consumer Care AG Basel, Switzerland
Bayer CropScience (Portugal)-Produtos para a
Agricultura, Lda Carnaxide, Portugal
Bayer CropScience Aktiengesellschaft Monheim am
Rhein, Germany
Bayer CropScience Beteiligungsgesellschaft mbH
Monheim am Rhein, Germany
Bayer CropScience Biologics GmbH Wismar, Germany
Bayer CropScience Deutschland GmbH Langenfeld,
Germany 100
Bayer CropScience Holding SA Lyon, France
Bayer CropScience Limited Cambridge, U.K.
Bayer CropScience NV Diegem, Belgium
Bayer CropScience S. r. l. Milan, Italy
Bayer CropScience Schweiz AG Muttentz, Switzerland
Bayer CropScience Vermögensverwaltungsgesellschaft
mbH Leverkusen, Germany
Bayer CropScience, S. L. Paterna, Spain
Bayer d. o. o. Belgrade, Serbia
Bayer d. o. o. Ljubljana, Slovenia
Bayer d. o. o. Zagreb, Croatia
Bayer Direct Services GmbH Leverkusen, Germany
Bayer East Africa Ltd. Nairobi, Kenya
Bayer Gastronomie GmbH Leverkusen, Germany
Bayer Gesellschaft für Beteiligungen mbH Leverkusen,
Germany
Bayer Global Investments B. V. Mijdrecht, Netherlands
Bayer HealthCare Manufacturing S. r. l. Milan, Italy
Bayer HealthCare SAS Loos, France
Bayer Hellas A. G. Athens, Greece
Bayer Hispania, S. L. Sant Joan Despi, Spain
Bayer Hungária Kft. Budapest, Hungary

Bayer Intellectual Property GmbH Monheim am Rhein, Germany
Bayer Israel Ltd. Hod Hasharon, Israel
Bayer Limited Dublin, Ireland
Bayer Limited Lemesos, Cyprus
Bayer Limited Egypt Cairo, Egypt
Bayer Ltd. Kiev, Ukraine
Bayer Medical Care B. V. Maastricht, Netherlands
Bayer Middle East FZE Dubai, United Arab Emirates
Bayer Nordic SE Espoo, Finland
Bayer Norway AS Oslo, Norway
Bayer NV Diegem, Belgium
Bayer Oy Turku, Finland
Bayer Parsian AG Tehran, Iran
Bayer Pharma Aktiengesellschaft Berlin, Germany
Bayer Portugal, Lda. Carnaxide, Portugal
Bayer Public Limited Company Reading, U.K.
Bayer R&I B. V. Maastricht, Netherlands
Bayer Real Estate GmbH Leverkusen, Germany
Bayer S. A. Casablanca, Morocco
Bayer S. A. S. Lyon, France
Bayer S. p. A. Milan, Italy
Bayer s. r. o. Prague, Czech Republic
Bayer Saudi Arabia LLC Jeddah, Saudi Arabia
Bayer Schering Pharma Aktiengesellschaft Berlin, Germany
Bayer Seeds B. V. Mijdrecht, Netherlands
Bayer Solution B. V. Mijdrecht, Netherlands
Bayer Sp. z o. o. Warsaw, Poland
Bayer Türk Kimya Sanayii Limited Sirketi Istanbul, Turkey
Bayer US B. V. Mijdrecht, Netherlands
Bayer Vital GmbH Leverkusen, Germany
Bayer Weimar GmbH und Co. KG Weimar, Germany
Bayer West-Central Africa S. A. Abidjan, Ivory Coast
Bayer World Investments B. V. Mijdrecht, Netherlands
Bayer, spol. sr. o. Bratislava, Slovakia
Bayer-Handelsgesellschaft mit beschränkter Haftung Leverkusen, Germany
Berlimed, S. A. Madrid, Spain
Berlipharm B. V. Weesp, Netherlands
Berlis AG Zurich, Switzerland
BGI Deutschland GmbH Leverkusen, Germany
Biogenetic Technologies B. V. Rotterdam, Netherlands
Chemion Logistik GmbH Leverkusen, Germany

FINANCIAL INFORMATION

General Description	The company does not make its financial statements public. The following information has been provided by private sources:
Year/Currency	2017 USD
Sales	1,900,000,000
Money Flow	Normal
Financial Figures	We also attach the latest financial statements of Bayer Aktiengesellschaft IMPORT FOB DOLLAR

Year	Amount
------	--------

There are not Import Fob Dollar informed

EXPORT FOB DOLLAR

Year	Amount
------	--------

There are not Export Fob Dollar informed

LEGAL FILINGS

Lawsuits	<p>Nektar Therapeutics et al v. Bayer Healthcare LLC Plaintiff: Baxalta US Inc., Nektar Therapeutics and Baxalta Incorporated Defendant: Bayer Healthcare LLC Case Number: 1:2018cv01355 Filed: August 31, 2018 Court: Delaware District Court Presiding Judge: Richard G Andrews Nature of Suit: Patent Cause of Action: 35:1 Jury Demanded By: Plaintiff</p> <p>ROSEMAN v. BAYER HEALTHCARE LLC et al, No. 1:2017cv13308 - Document 34 (D.N.J. 2018) Court Description: OPINION. Signed by Judge Robert B. Kugler on 5/11/2018. (dmr)</p> <p>Bayer Healthcare LLC et al v. Apotex, Inc. et al Plaintiff: Bayer HealthCare Pharmaceuticals Inc. and</p>
-----------------	---

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Bayer Healthcare LLC
Defendant: Apotex Corp. and Apotex, Inc.
Case Number: 1:2018cv01465
Filed: September 21, 2018
Court: Delaware District Court
Presiding Judge: Leonard P Stark
Nature of Suit: Patent - Abbreviated New Drug
Application(ANDA)
Cause of Action: 35:271
Jury Demanded By: None

Bayer HealthCare LLC v. Nektar Therapeutics et al
Plaintiff: Bayer HealthCare LLC
Defendant: Nektar Therapeutics, Baxalta Incorporated
and Baxalta US Inc.
Case Number: 3:2017cv05055
Filed: August 30, 2017
Court: California Northern District Court
Office: San Jose Office
County: XX US, Outside State
Presiding Judge: Lucy H. Koh
Referring Judge: Howard R. Lloyd
Nature of Suit: Patent
Cause of Action: 28:2201
Jury Demanded By: Plaintiff

Curran v. Bayer Healthcare LLC et al, No.
1:2017cv07930 - Document 69 (N.D. Ill. 2018)
Court Description: MEMORANDUM Opinion and Order.
The Court denies defendant's motion 28 to transfer.
The Court grants defendant's motion 28 to dismiss.
Plaintiff's complaint is dismissed without prejudice.
Plaintiff is granted leave to file an amended complaint
by June 25, 2018. Status hearing remains set for June
28, 2018 at 9:30 a.m. Signed by the Honorable Jorge L.
Alonso on 5/30/2018. Notices mailed by judge's staff
(ntf,)

Patterson et al v. Bayer Healthcare LLC et al, No.
6:2017cv00048 - Document 40 (E.D. Ky. 2018)
Court Description: OPINION & ORDER, Case
Terminated. ORDERED: (1) This matter is
REMANDED to the docket of the Perry County Circuit
Court; (2) All remaining motions are DENIED AS
MOOT; and (3) This case is STRICKEN from the
Courts active docket. Signed by Judge Karen K.
Caldwell on 4/23/2018.(RBB)cc: COR, paper copy to
Perry Circuit Court

Trademarks

RIKOS v. BAYER HEALTHCARE, LLC, No.
2:2011cv03017 - Document 175 (D.N.J. 2017)
Court Description: OPINION. Signed by Judge John
Michael Vazquez on 04/17/2017. (ek)
TASTISMOOTH - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 85364147
Serial Number85364147
Registration Number4234867
Word MarkTASTISMOOTH
Status700 - Registered
Status Date2012-10-30
Filing Date2011-07-06
Registration Number4234867
Registration Date2012-10-30
Mark Drawing4000 - Standard character mark Typeset
Published for Opposition Date2011-12-13
Attorney NameVanessa A. Ignacio
Law Office Assigned Location CodeL70
Employee NameDELGIZZI, RONALD ERNES

CONTOUR - Trademark Details
Status: 800 - Registered And Renewed
Image for trademark with serial number 78097718
Serial Number78097718
Registration Number2863570
Word MarkCONTOUR
Status800 - Registered And Renewed
Status Date2014-07-02
Filing Date2001-12-11
Registration Number2863570
Registration Date2004-07-13
Mark Drawing1000 - Typeset:
Word(s)/letter(s)/number(s) Typeset
Published for Opposition Date2002-08-13
Attorney NameKatie Blakley
Law Office Assigned Location CodeM70
Employee NameBRACEY, KAREN E

BREEZE - Trademark Details
Status: 800 - Registered And Renewed
Image for trademark with serial number 78098975
Serial Number78098975
Registration Number2815718
Word MarkBREEZE
Status800 - Registered And Renewed
Status Date2014-02-21
Filing Date2001-12-18
Registration Number2815718

Registration Date 2004-02-17
Mark Drawing 1000 - Typeset:
Word(s)/letter(s)/number(s) Typeset
Published for Opposition Date 2002-11-05
Attorney Name Katie Blakley
Law Office Assigned Location Code M30
Employee Name WILLIAMS, IRENE D

MYCELEX - Trademark Details
Status: 800 - Registered And Renewed
Image for trademark with serial number 73059788
Serial Number 73059788
Registration Number 1060584
Word Mark MYCELEX
Status 800 - Registered And Renewed
Status Date 2007-03-07
Filing Date 1975-08-06
Registration Number 1060584
Registration Date 1977-03-08
Mark Drawing 1000 - Typeset:
Word(s)/letter(s)/number(s) Typeset
Attorney Name Jeffrey M. Gitchel

QUELLIN - Trademark Details
Status: 700 - Registered
Image for trademark with serial number 86051795
Serial Number 86051795
Registration Number 4700700
Word Mark QUELLIN
Status 700 - Registered
Status Date 2015-03-10
Filing Date 2013-08-29
Registration Number 4700700
Registration Date 2015-03-10
Mark Drawing 4000 - Standard character mark Typeset
Published for Opposition Date 2014-06-17
Attorney Name Jeffrey M. Gitchel
Law Office Assigned Location Code M10
Employee Name VOHRA, SANJEEV KUMAR
PYRROLOTRIAZINE DERIVATIVES USEFUL FOR
TREATING HYPER-PROLIFERATIVE DISORDERS
AND DISEASES ASSOCIATED WITH
ANGIOGENESIS
Publication number: 20130225809
Abstract: This invention relates to pyrrolotriazine
compounds, pharmaceutical compositions containing
such compounds and the use of those compounds and
compositions for the prevention and/or treatment of
hyper-proliferative disorders and diseases associated

Patents Registered

with angiogenesis.

Type: Application

Filed: December 20, 2012

Publication date: August 29, 2013

Applicant: Bayer HealthCare LLC

Inventor: Bayer HealthCare LLC

METHODS OF USING AN ELECTROCHEMICAL BIOSENSOR

Publication number: 20130161206

Abstract: According to one embodiment of the present invention, an electrochemical sensor (10) for detecting the concentration of analyte in a fluid test sample is disclosed. The sensor (10) includes a counter electrode having a high-resistance portion for use in detecting whether a predetermined amount of sample has been received by the test sensor.

Type: Application

Filed: February 25, 2013

Publication date: June 27, 2013

Applicant: Bayer HealthCare LLC

Inventor: Bayer HealthCare LLC

Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions

Publication number: 20130131122

Abstract: A compound of Formula (I): salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by raf, VEGFR, PDGFR, p38 and ft-3.

Type: Application

Filed: November 5, 2012

Publication date: May 23, 2013

Applicant: BAYER HEALTHCARE LLC

Inventor: Bayer Healthcare LLC

METHOD OF DIFFERENTIATING BETWEEN BLOOD AND CONTROL SOLUTIONS CONTAINING A COMMON ANALYTE

Publication number: 20130183699

Abstract: Glucose measured in blood samples is distinguished from glucose measured in the control solutions used to test the optical instruments which make such measurements. The control solutions contain a labeling substance recognized by the optical instrument to distinguish glucose measurements made of control solutions from those made of blood samples.

Type: Application
Filed: March 6, 2013
Publication date: July 18, 2013
Applicant: Bayer HealthCare, LLC
Inventor: Bayer HealthCare, LLC

Concentration Determination in a Diffusion Barrier Layer

Publication number: 20130098778
Abstract: The present invention relates to improved electrochemical biosensor strips and methods for determining the concentration of an analyte in a sample. By selectively measuring a measurable species residing in a diffusion barrier layer, to the substantial exclusion of the measurable species residing exterior to the diffusion barrier layer, measurement errors introduced by sample constituents, such as red blood cells, and manufacturing variances may be reduced.

Type: Application
Filed: November 6, 2012
Publication date: April 25, 2013
Applicant: BAYER HEALTHCARE LLC
Inventor: Bayer HealthCare LLC

ANALYTE MONITOR

Publication number: 20130171028
Abstract: An analyte meter for an analyte test strip includes a light source configured to emit a light having a wavelength substantially similar to the maximum absorption band of Hb, an optics assembly configured to direct the light emitted by the light source to a test strip, and a photodetector configured to quantitatively detect light emanating from the test strip and to generate a signal correlating to an analyte concentration in the test strip.

Type: Application
Filed: December 28, 2012
Publication date: July 4, 2013
Applicant: BAYER HEALTHCARE LLC
Inventor: BAYER HEALTHCARE LLC

Mediator For Test Sensor

Publication number: 20130126350
Abstract: A method of forming a 3-phenylimino-3H-phenothiazine or a 3-phenylimino-3H-phenoxazine mediator includes providing a first reactant including phenothiazine or phenoxazine, providing a first solvent, providing a second reactant and providing a second

solvent. The first reactant, first solvent, second reactant and second solvent are combined to form a reactants solution. Sodium persulfate is added to the reactants solution to couple the first and second reactants resulting in a reaction solution including the 3-phenylimino-3H-phenothiazine or the 3-phenylimino-3H-phenoxazine mediator.

Type: Application

Filed: December 17, 2012

Publication date: May 23, 2013

Applicant: BAYER HEALTHCARE LLC

Inventor: Bayer Healthcare LLC

ANALYTE-TESTING DEVICE

Publication number: 20130044119

Abstract: A device adapted to determine an analyte concentration of a fluid sample using a test sensor. The device comprises a display adapted to display information to a user. The device further comprises at least one user-interface mechanism adapted to allow the user to interact with the device. The device further comprises a body portion including at least one opening formed therein, the at least one opening being of sufficient size to receive the test sensor. The device further comprises a memory adapted to store a plurality of stored analyte concentrations. The device further comprises a processing feature adapted to inhibit the stored analyte concentrations from being displayed on the display.

Type: Application

Filed: October 22, 2012

Publication date: February 21, 2013

Applicant: BAYER HEALTHCARE, LLC

Inventor: Bayer HealthCare, LLC

Devices and Methods for Integrated Continuous Manufacturing of Biological Molecules

Publication number: 20130344585

Abstract: The present invention relates to a process and apparatus for purifying a molecule of interest from a heterogeneous clarified fluid mixture. The apparatus of the invention generally comprises a continuous perfusion fermentation system, a continuous particle removal system integrated with the perfusion fermentation system; and a continuous purification system integrated with the particle removal system, which is maintained under sterile conditions. The process comprises filtering a heterogeneous clarified fluid mixture by continuous ultrafiltration at a specific

<p>Renewals</p> <p>UCC (Uniform Commercial Code)</p> <p>OFAC Sanctions List Search</p>	<p>flow rate below the transition point of the molecule of interest in the pressure-dependent region of the flux versus TMP curve, wherein the specific flow rate is maintained substantially constant throughout the continuous ultrafiltration.</p> <p>Type: Application Filed: March 12, 2013 Publication date: December 26, 2013 Applicant: BAYER HEALTHCARE LLC Inventor: BAYER HEALTHCARE LLC No records found</p> <p>No records found</p> <p>The company is not listed in the OFAC list.</p>
---	--

SUMMARY

<p>Summary</p>	<p>Founded in 1953, Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products.</p> <p>The company has approximately 800 employees and generates an estimated USD 1,9 billion in annual revenue.</p> <p>The company imports from Hong Kong, China and Taiwan, and exports worldwide, operating within national and international markets.</p> <p>The company is a subsidiary of Bayer Aktiengesellschaft.</p> <p>This has been an ACTIVE company incorporated in DELAWARE in 2002.</p>
-----------------------	--

RISK INFORMATION

<p>Debts</p> <p>Payments</p> <p>Cash Flow</p>	<p>Controlled</p> <p>Regular</p> <p>Normal</p>
--	--

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

Suggested Credit Line USD 1 000 000
State ACTIVE

INTERVIEW

First Name Sam
Position Operator
Comments
The person contacted confirmed trade name, this telephone number 862-404-3000, the operative address of the company (100 Bayer Boulevard Whippany, NJ 07981 USA), this email contactbayer@bayer.com, and website www.bayer.us.

She confirmed that the company has branches in USA and operations worldwide.

She refused to provide further information.

We also tried calling at the telephone number provided in the order (+1 913-268-2142) but the person contacted, John Chester, was not available to answer the phone call.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 70.67
UK Pound	1	INR 90.14
Euro	1	INR 79.88
USD	1	INR 69.88

Note : Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Analysis Done by :	NIS
Report Prepared by :	SYL

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

RATING EXPLANATIONS

Credit Rating	Explanation	Rating Comments
A++	Minimum Risk	Business dealings permissible with minimum risk of default
A+	Low Risk	Business dealings permissible with low risk of default
A	Acceptable Risk	Business dealings permissible with moderate risk of default
B	Medium Risk	Business dealings permissible on a regular monitoring basis
C	Medium High Risk	Business dealings permissible preferably on secured basis
D	High Risk	Business dealing not recommended or on secured terms only
NB	New Business	No recommendation can be done due to business in infancy stage
NT	No Trace	No recommendation can be done as the business is not traceable

NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.

This score serves as a reference to assess SC's credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors are as follows:

- Financial condition covering various ratios
- Company background and operations size
- Promoters / Management background
- Payment record
- Litigation against the subject
- Industry scenario / competitor analysis
- Supplier / Customer / Banker review (wherever available)

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.